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Abstract
Aims Follow-up studies of patients with cardiac syndrome
X (CSX) generally report good prognosis. However, some
recent studies report an adverse outcome for women.
Methods and results Structured literature search and meta-
analysis for studies regarding prognosis of cardiac syn-
drome X patients. We identified 85 studies, ultimately
selecting 16 for inclusion. Meta-analysis yielded a pooled
major cardiac event percentage of 1.5% per 5 years and a
pooled vascular event percentage of 4.8% per 5 years (n016
studies, n01694 patients). Fourteen studies reported upon
the recurrence rate of angina pectoris: the pooled percentage
of angina recurrence was 55% (n01336 patients).
Conclusion The present review of recent archival literature
demonstrates an overall major cardiac event rate of 1.5% per
5 years. Although this is an excellent prognosis for CSX
patients, the quality of life is impaired because of the high
recurrence rate of angina pectoris (55%).
Keywords Cardiac syndrome X .Microvascular angina .
Angina pectoris AND normal coronary arteries . Prognosis
Introduction
Cardiac syndrome X (CSX) is the syndrome of angina
pectoris during a positive stress test despite a normal coro-
nary arteriogram. CSX is an important clinical entity [1–19].
About 3–11% of patients undergoing coronary angiography
because of typical chest pain have normal coronary arteries
and qualify for the definition of CSX [19].
Follow-up studies of patients with CSX generally report
good prognosis [7, 9]. However, a recent study reported an
adverse cardiovascular outcome for women with chest pain
and normal coronary arteries [6].
Therefore, the present paper reviews the recent literature
on CSX to discuss in detail the long-term prognosis.
Methods of identifying and selecting the literature
A review and meta-analysis of the literature was conducted
with a comprehensive search of the PubMed database to
identify clinical studies on CSX that considered prognosis.
The prognosis of CSX patients was derived from the cardiac
event rate per year for each study and the recurrence rate of
angina (when included in the studies).
Studies were eligible for review if they met the following
standardised inclusion criteria [20–22]: Full-length articles;
studies including CSX or patients with angina and normal
coronary arteries; minimum number of 10 patients; studies
presenting follow-up data of more than 2 years; and publi-
cation dates between April 1985 and February 2010.
The criteria for excluding studies were: metabolic syn-
drome X; studies including patients with near-normal coro-
nary angiography (CAG) results; and studies of patients
with myocardial infarction and/or cardiomyopathy were
excluded.
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In detail, the PubMed database was used to identify
papers in which definitions and prognosis for CSX are
described via the following terms:
‘((Prognosis or follow up) AND ((((cardiac syndrome
x OR (angina pectoris AND normal coronary arteries)
OR microvascular angina)) AND (((“microvascular angi-
na”[TIAB] NOT Medline[SB]) OR “microvascular angi-
na”[MeSH Terms] OR cardiac syndrome x[Text
Word]))) AND ((“syndrome x”[All] OR (((angina pecto-
ris) OR (chest pain)) AND normal AND (coronary[tw]
OR angiogra*[tw])) OR (microvascular angina)))) AND
((Humans[Mesh]) AND (English[lang]) AND (adult
[MeSH])))’; with limits set to English language and
humans.
The search strategy identified 85 studies from PubMed.
These became the source population for this review. The
titles were screened for eligibility by one of the reviewers
(I.V.), followed by two reviewers (I.V. and P.R.) inde-
pendently assessing the abstracts by consensus. In this
initial screening a total of 23 articles were excluded because
of:
(a) Metabolic syndrome X, myocardial infarction and
tako-tsubo cardiomyopathy (14 references).
(b) Non-performance of coronary angiography (2
references).
(c) Studies with coronary spasm (3), case report (1), anti-
phospholipid syndrome (1) and non-obstructive coro-
nary artery disease (2) in the title.
The titles of the remaining papers contained cardiac
syndrome X (44 papers), normal coronary arteries (14
papers) and microvascular angina (4 papers).
The full texts of all 62 papers were retrieved for further
selection, notably as to whether they considered prognosis.
Only 17 included prognosis, but checking the references
from all 17 resulted in another 4 papers being selected [1,
6, 12, 14]. Of these remaining 21 papers, 9 described CSX,
11 described AP and normal coronary arteries (NCA), and 1
described microvascular angina.
Finally, the 21 papers were independently surveyed by
two authors (IV and PR) with respect to the definition of
CSX and prognosis. This resulted in 5 papers being exclud-
ed as follows: an NCA study [23] also included minimal
lesions of the coronary arteries with a reduction in diameter
of less than 50%; one turned out to be only a letter [24]; 2
intervention studies did not report cardiac events [25, 26];
and another appeared to be an intervention study of only 7
patients [27], whereas the agreed minimum number of
patients for our review was 10.
This survey left 16 papers for the present review. These
papers covered a total of 1694 patients. For each paper we
extracted the number of patients; cardiovascular event rates;
percentage of female/male patients (for studies including
both female and male patients); and the percentage of
patients with recurrent chest pain. In more detail:
(1) Major adverse cardiac event rates included cardiac
death, myocardial infarction and revascularisation as
defined by the most recent ACC/AHA guidelines 2010
and other studies [28–30].
(2) The vascular events included myocardial infarction,
cardiac death, development of CAD, heart failure,
and the occurrence of cerebrovascular events.
(3) Since some of the studies had different follow-up peri-
ods, we normalised the event rates to those per 5 years.
(4) Before calculation of the pooled estimates of major
cardiac event rates, cardiovascular event rates, chest
pain recurrence rates and gender distribution, the het-
erogeneity of these values was tested using calculation
of I2 and the Chi-square test. The effects of follow-up
period, gender distribution and mean age of the pop-
ulations upon the cardiovascular event rates were stud-
ied using regression analysis: P values<0.05 were
considered to be significant.
Results
Table 1 lists the 16 studies included in this review. Note that
(a) 2 studies did not report the frequency of chest pain [3, 6],
(b) the follow-up period varied widely, from 2.4 years to
14 years, and (c) 3 studies did not have male and female
patients [1, 3, 6].
CSX prognosis
The three most important results relating to prognosis are:
(1) The major cardiac event rate varied from 0% to 3.8%
per 5 years, with a pooled value of 1.5% per 5 years
(95% CI: 1–2.2%, n01694 patients) (Fig. 1). There
was no significant heterogeneity between included
studies regarding the major cardiac event rate (p0
0.074). The estimated annual major cardiac event rate
was 0.3%. This includes myocardial infarction, revas-
cularisation and cardiovascular death (Table 1).
(2) The general cardiovascular event rate varied from 0%
to 16.7% per 5 years, with a pooled value of 4.8% for
5 years (95% CI: 3.8–5.9%). However, there was sig-
nificant heterogeneity (p<0.001) (Fig. 2).
(3) There were 14 studies with 1336 patients for analysis
of recurrent chest pain. The recurrence rate varied
between 13.2% and 89.9% for the different study pop-
ulations, with a pooled value of 55% (95% CI: 53–
58%, n01336 patients). There was significant hetero-
geneity (p<0.001) (Fig. 3).
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The remaining results are:
(4) The major cardiac event rate was not related to the length
of follow-up (R200.0043), mean age (R200.000006)
and percentage of female patients (R200.0268).
(5) The total vascular cardiac event rate per study was not
related to the length of follow-up (R2 00.0011), mean
age (R200.238) and percentage of female patients
(R200.063).
Discussion
Overall cardiac event rates
This systematic review shows that the CSX prognosis in
terms of the overall cardiac event rate is excellent, with a
risk of myocardial infarction or cardiovascular death of
1.5% per 5 years. The Framingham Heart Study reported
Table 1 Cardiac syndrome X











Bugiardini [1] 2004 42 51.6±8.8 0 10.3 1 0 13 31 –
Chauhan [2] 1993 41 46±4 39 2.9 0 0 0 64 –
Delcour [3] 2009 48 60.9±12 100 7.4 0 1 5 – – 6 CVA
Foussas [4] 1998 160 50 69 2.5 1 2 0 59 –
Fragasso [5] 2009 34 56 20 14±2 0 2 2 65 – 1 LV dysfunction
Gulati [6] 2009 318 53.6±10.4 0 5.2 5 3 0 – – 8 CVA; 10 LV dysfunction
Kaski [7] 1995 99 48.5±8 21 7±4 0 0 0 89 – 1 LV dysfunction
Lamendola [8] 2008 155 58.9±10 26 11.4±6.5 0 0 3 48 21
Leu [9] 2005 92 63.9±10.5 78 2.6±1.2 0 0 0 13 9 1 LV dysfunction; 3 CVA
Lichtlen [10] 1995 176 48.3 65 12.4 2 4 8 81 12
Radice[11] 1995 30 51±6 27 12.3±3.5 0 0 0 33 27
Scholz [12] 2002 173 54±7.8 59 12.0±2.9 10 0 6 34 –
Shintani [13] 2003 43 55±8 7 6.4±3.8 0 0 0 44 –
Sullivan [14] 1994 138 50.0 55 2.4 0 1 0 70 –
Sun [15] 2001 59 61±5 88 7.1±1.4 0 1 0 76 – 10 LV dysfunction
Suzuki [16] 2002 86 59±9 41 7.2±3.4 0 0 0 35 2
– 0 non-available
CAD coronary artery disease, CAG coronary angiography; CVA cerebrovascular accident; FU follow-up; LV left ventricular;MI myocardial infarction
Fig. 1 Major cardiac event rate Fig. 2 General cardiovascular event rate
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annual hard (death, myocardial infarction) coronary event
rates of 1.2% (men<65 years); 2.7% (men>65 years); 0.5%
(women<65 years); and 1.6% (women>65 years). These
rates are all higher than the major adverse cardiac event rate
for CSX patients determined from our systematic review.
The lower cardiac event rates for CSX patients suggest
that they may benefit from protective factors against coro-
nary macrovascular disease. These factors could be (a)
cardioprotective medication, (b) a healthier lifestyle to avoid
angina and myocardial infarction, e.g. becoming non-
smokers, and (c) another biological mechanism. A possible
example of the last mentioned is the observation that platelet
reactivity decreases after stress in patients with CSX, in
contrast to patients with coronary artery disease (CAD)
[31, 32]. On the other hand, the better prognosis of CSX
patients compared with the general population may result
from a selection process. CSX patients all have, by defini-
tion, normal coronary arteries, which is not necessarily the
case in the general population. The difference in prevalence
of coronary atherosclerosis between CSX patients and the
general population may explain the difference in cardiac
event rates.
The notion of the benign nature of CSX has been chal-
lenged by reports of a high risk of future cardiac events in
patients with angina and normal coronary arteries [1, 33,
34]. A recent study, named the Women’s Ischaemia Syn-
drome Evaluation (WISE) study, involved 540 symptomatic
women referred for coronary angiography and followed up
for a mean of 5.2 years. The control group was asymptom-
atic, and consisted of community-based age- and race-
matched women with no history of heart disease, and who
were followed up for 10 years.
The WISE study showed a cardiovascular event rate of
7.9% per 5 years for women with angina and normal
coronary arteries (CSX), compared with 2.4% per 5 years
for the asymptomatic control group [6]. The WISE study
CSX event rate lies outside the 95% confidence interval of
3.8%–5.9% per 5 years that we found from our reviewed
studies.
However, the rate of cardiovascular death was not signif-
icantly different between the CSX women and the control
(asymptomatic) women in the WISE study. The increased
cardiovascular event rate in symptomatic women with nor-
mal coronary arteries was largely accounted for by an in-
creased incidence of hospitalisation for heart failure and
stroke. It remains unexplained why the incidence of heart
failure and stroke are increased in this specific population,
although microvascular dysfunction might precede macro-
vascular atherosclerosis.
CSX and non-obstructive CAD cardiac event rates
It is important to distinguish between CSX, with normal
coronary arteries, and non-obstructive CAD [19]. The car-
diac event rate for CSX patients is significantly better than
that for patients with angina and non-obstructive CAD. This
is illustrated by Sicari et al. [35], who reported that a
subgroup of patients with angina and non-obstructive
CAD (incorrectly identified as CSX), and with positive
dipyridamole echocardiography tests, had a survival rate of
only 76% after 7.1 years follow-up.
Five-year cardiac event rates for cardiovascular events
were significantly different for three subgroups in the WISE
study: 16% per 5 years for women with angina and non-
obstructive CAD (stenosis <50%); 7.9% per 5 years for
women with angina and normal coronary arteries (CSX);
and 2.4% per 5 years for the asymptomatic control group
(P≤0.002) [6]. Hence, in this large study a higher incidence
Fig. 3 Chest pain recurrence
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of events in symptomatic women with non-obstructed CAD
was found compared with patients with symptoms and nor-
mal coronary arteries.
CSX and coronary microvascular dysfunction
Lanza and Crea recently proposed to rename CSX as stable
primary coronary microvascular dysfunction (CMVD) [36].
This proposal was made on the premise that abnormalities in
the coronary microcirculation are the probable cause of CSX
ischaemia and angina. However, Herzog obtained contem-
porary positron emission tomography (PET) data that sug-
gest an increased cardiac event rate for patients with
microvascular dysfunction, irrespective of abnormalities in
the epicardial coronary arteries [37]. (Note: this study was
not included in our literature review because CAGs were not
performed.)
In the study by Herzog the patients with a reduced
flow reserve, defined as a CFR<2.0, had a higher
annual cardiac event rate and a higher risk of cardiac
death, and this included patients with a normal perfu-
sion PET [37]. Specifically, a subgroup of patients with
normal perfusion but impaired CFR had a significantly
higher major annual cardiac event rate (6.25%) com-
pared with patients with a normal CFR (1.4%). Also,
the annual cardiac death rate was higher: 3.1% for
patients with normal perfusion but impaired CFR, com-
pared with 0.5% for patients with normal CFR. Thus it
is possible for patients with a normal perfusion, who are
therefore unlikely to have epicardial coronary obstruc-
tive disease, to already have a reduced CFR, and that
this is associated with a higher cardiac event rate or
higher risk of cardiac death. The reduced CFR was
most likely caused by microvascular or endothelial dys-
function [37]. Therefore one should be cautious about
equating CSX (which has a generally good prognosis)
with coronary microvascular dysfunction.
Limitations to the significance of the study by Her-
zog et al. are (a) the relatively small number of patients
in the subgroup with normal perfusion and impaired
CFR (n032), and (b) that after 10 years follow-up the
impaired CFR could not predict any cardiac event in
this subgroup [37]. Hence larger prospective studies are
needed. Be that as it may, we may conclude that a
distinguishing diagnosis between CSX and CMVD
requires evaluation of the distal compartment (intramural
arterioles) as well as the proximal compartment (the
large epicardial coronary arteries).
Recurring chest pain
As stated earlier, recurrence of chest pain occurred in an
average of 55% of the CSX cases included in our systematic
review. In the study by Lantinga et al., 85% had at least
weekly episodes of chest pain up to 1 year after the
angiograms, with the pain unchanged or even worse;
and 33% underwent at least one more coronary angiography
[38].
The most important therapy consists of reassurance,
risk factor modification, and symptom relief (ACC/AHA
guidelines 2002, www.acc.org/qualityandscience/clinical/
statements.htm). There are conflicting data about the
exact cause of chest pain in patients with CSX, There
is evidence for ischaemia [17, 39], and alternatively,
psychological factors such as an increased anxiety may
play a role in CSX [18]. The number of pain episodes
can be reduced by β-blockers, calcium antagonists,
nitrates and imipramine, which is particularly successful
[40]. Similar success has been claimed for oestrogen
replacement therapy [41, 42]. In a patient with coronary
spasms we found an increase of the myocardial blood
flow and decrease of symptoms using bosentan, an
endothelin receptor antagonist [43]. However, the thera-
peutic measures remain largely empirical, and the symp-
toms persist in many patients.
Limitations
Systematic reviews are hampered by publication bias, i.e.,
the preferential publication of studies with significant posi-
tive results rather than those with negative results. However,
in studies regarding prognosis and survival this phenome-
non is probably less frequent compared with studies evalu-
ating therapeutic strategies.
Another potential problem is that clinical prognostic
studies are almost inevitably different in their length of
follow-up, which can affect the study results because
longer follow-up periods might yield more exact prog-
nostic figures. However, in our review we found no
relation between the length of follow-up and event
rates.
There are possible limitations owing to varying in-
clusion criteria for the different studies. These variations
can cause heterogeneous meta-analysis results. For ex-
ample, we found in earlier work that there were more
than 50 different criteria (nine different inclusion criteria
and 43 different exclusion criteria) for CSX, resulting in
a varying reported incidence of CSX [19]. Also, the hetero-
geneity of the different study populations may have contrib-
uted to the heterogeneity that we found with respect to the
prognoses from the studies.
On the other hand, the advantages of reviews and meta-
analyses are an increase in statistical power, the ability to
assess sources of heterogeneity, and the provision of overall
estimates of prognostic variables.
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Conclusions
The present review found an overall major adverse cardiac
event rate of 1.5% per 5 years. This represents a better
prognosis compared with the general population. However,
angina pectoris in CSX is recurrent and persistent in 55% of
the patients, and significantly impairs the quality of life.
Whether CSX patients benefit from protective factors
against acute coronary events is a challenging issue that
should be addressed in future studies.
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